The finding suggests that predicting how a person’s cancer will evolve may lie in their inherited genetic material.
The study results have the potential to establish a new standard for using this method to actively monitor prostate cancer.
The observation helps explain why, as people age, the prostate tends to grow, leading to an increased risk for cancer and other conditions.
Research brief: The study recommends that the new procedure should become the standard of care.
50% of treatments could have been avoided using the new tool, a UCLA-led study finds.
Combining biopsy strategies allowed doctors to find up to 33% more cancers.
Research Brief: Researchers compared the system’s results with readings by UCLA doctors who had more than 10 years of experience.
A long-term, UCLA-led study finds that those with low- or intermediate-risk disease can safely cut treatment to four to five days.
Previous research hinted that small cell cancers from different organs may be driven by common mechanisms, but the new study is the first to so clearly describe the steps in their evolution.
The study could lead to new treatments for a range of advanced epithelial cancers such as lung, prostate and bladder cancers.
The state-funded IMPACT program provides access to free treatment for uninsured and underinsured men in California.
UCLA chemistry professor helped develop Erleada, which was recently approved by the FDA for treating an especially lethal form of prostate cancer.
The research is the first of its kind to compare results between radiotherapy treatments that are higher than the standard dose and traditional treatments, such as radiation and prostatectomy.
Software developed by a UCLA urologist helps men avoid decisions they might regret.
UCLA researchers have discovered a previously unrecognized type of progenitor cell that is found in uncommonly high numbers in inflamed areas of the gland.
Researchers at the UCLA Jonsson Comprehensive Cancer Center say findings in new study will help physicians and patients make informed decisions.
The researchers found that an experimental drug called CD532, which changes the structure of a key protein, reduced the size of tumors in mice by 80 percent.
Less than 5 percent of men who chose to forgo aggressive treatment are being monitored as closely as they should be
For the first time, researchers have described the cost throughout the entire treatment process — from the initial doctor’s visit to follow-up appointments.
Researchers say this research gives important insight into the cellular nature of aggressive prostate cancer, which will aid in the development of better treatments.
The sports network told the story of how Andrew Goldstein’s courageous story of coming out as gay to his college lacrosse teammates many years ago led to a friendship with a boy who contemplated suicide after coming out.
Results of the study provide evidence that drugs used to treat diabetes could be used to reduce tumor growth in pancreatic and prostate cancers.
Radiation therapy is the most common treatment for men with prostate cancer, but it may not always be worthwhile.
UCLA study finds over-treatment for prostate cancer patients with life expectancies of fewer than 10 years
National guidelines recommend that men in these cases should not be treated with radiation or surgery, since they are unlikely to live long enough to benefit from treatment.
Study finds that that men who aren’t well educated about their disease have a much more difficult time making treatment decisions. This "decisional conflict" could negatively impact their long-term outcomes.